Stelios Andreadis

PhD

photo of Stelios

Stelios Andreadis

PhD

Stelios Andreadis

PhD

Research Topics

Stem cells for vascular tissue engineering; signaling pathways in cell-cell adhesion and wound healing; lentiviral vectors and lentiviral microarrays for high-throughput gene expression analysis and gene discovery

Contact Information

908 Furnas Hall

Buffalo NY, 14260

Phone: (716) 645-1202

Fax: (716) 645-3822

sandread@buffalo.edu

Biography

Stelios T. Andreadis received his M.S. (Applied Mathematics) and Ph.D. degree in Chemical Engineering from the University of Michigan studying the dynamics of retroviral gene transfer for gene therapy. He then pursued postdoctoral training at the Center for Engineering in Medicine at Harvard Medical School, where he worked in the areas of gene therapy, tissue engineering and regenerative medicine. Currently he serves as SUNY Distinguished Professor of Chemical and Biological Engineering, Biomedical Engineering and Member of the Center of Excellence in Bioinformatics and Life Sciences at the University at Buffalo, State University of New York. He is also the Director of the Stem Cells in Regenerative Medicine (SCiRM) Training Program that was recently funded by NYSTEM to train students in stem cell biology and bioengineering and applications of stem cells in regenerative medicine. He served as CBE department Chair for two terms from 2012 to 2018.

His research interests span a wide spectrum from fundamental to technological to pre-clinical/translational research. He has made significant research contributions in the areas of stem cell bioengineering; vascular, skin and gland tissue engineering and regeneration; molecular design of biomaterials; protein and gene delivery, and lentiviral arrays for high throughout pathway analysis of stem cell differentiation and reprogramming. He co-founded a company (Angiograft, LLC) to commercialize the cell-free vascular grafts that were developed in his laboratory as arterial replacement grafts for treatment of cardiovascular disease.

Professor Andreadis’ research has received continuous funding since 1999 from NIH, NSF, NYSTEM and private foundations (Whitaker, Oishei), totaling more than $20 million. He is the recipient the Whitaker Foundation Young Investigator Award (1999), the NSF CAREER Award (2000), the Exceptional Scholar Young Investigator Award (UB, 2003), Exceptional Scholar: Sustained Achievement Award (UB, 2009) and the SUNY Chancellor’s Award for Excellence in Scholarship (2014). He was elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE, 2009) and of the Biomedical Engineering Society (BMES, 2016). In 2018 he was promoted to the rank of SUNY Distinguished Professor. He has published 140 peer-reviewed publications and conference proceedings and delivered more than 75 invited seminars. He has advised 28 Ph.D. students, 18 M.S. students, 4 post-doctoral research fellows and more than 40 undergraduate researchers.

His former Ph.D. students hold tenured or tenure-track academic positions (U of South Florida, UB, IIT Kanpur in India, The Capital University of Medical Sciences in Beijing, China); post-doctoral positions at top Universities (Harvard, Stanford, Johns Hopkins, Univ. of Pennsylvania); or research and leadership positions in leading pharmaceutical/biotechnology companies (Shire Pharmaceuticals, Bristol-Myers Squibb, Merck, Biogen, Life Technologies, MedImmune and others).

Read more about Stelios Andreadis

Notably, his research group discovered that the pluripotency factor, Nanog reversed aging of stem cells yielding functional stem cells and may lead to more functional and rejuvenated tissues in patients.

In the area of stem cell reprogramming, his group recently reported the novel finding that skin stem cells can be reprogrammed into neural crest stem cells and their derivatives, including neurons, Schwann cells and melanocytes. This reprogramming strategy does not require genetic modification thereby providing an abundant, highly accessible and autologous source of stem cells for potential treatment devastating diseases of the peripheral and central nervous system, for which cell sourcing remains a severe impediment.

Finally, his group has pioneered cell-free tissue engineered vascular arterial grafts which are transplantable and functional. These pioneering studies have led to a start-up (Angiograft, LLC) bring these cell-free vascular grafts to clinical trials and for wide applications for vascular diseases of the heart, brain, and extremities.

He received his MS (Applied Mathematics) and PhD degree in Chemical Engineering from the University of Michigan in the dynamics of retroviral gene transfer for gene therapy. He then pursued postdoctoral training at the Center for Engineering in Medicine at Harvard Medical School, where he trained in the areas of gene therapy, tissue engineering and regenerative medicine. Currently he serves as Professor and Chair of Chemical and Biological Engineering, Professor of Biomedical Engineering and is a member of the UB Center of Excellence in Bioinformatics and Life Sciences. He is also the Director of the Stem Cells in Regenerative Medicine (SCiRM) Training Program that was recently funded by NYSTEM to train students in stem cell biology and bioengineering and applications of stem cells in regenerative medicine.

Professor Andreadis’ research has received continuous funding since 1999 from NIH, NSF, NYSTEM and private foundations (Whitaker, Oishei), totaling more than $18 million. Among his numerous accolades, Professor Andreadis is the recipient the Whitaker Foundation Young Investigator Award (1999), the NSF CAREER Award (2000), the Exceptional Scholar Young Investigator Award (UB, 2003), Exceptional Scholar: Sustained Achievement Award (UB, 2009) and the SUNY Chancellor’s Award for Excellence in Scholarship (2014). He was elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE, 2009) and of the Biomedical Engineering Society (BMES, 2016). With his laboratory colleagues he has published more than 135 peer-reviewed publications and conference proceedings and delivered more than 70 invited seminars. He has advised 24 Ph.D. students, 16 M.S. students, 4 post-doctoral research fellows and more than 40 undergraduate researchers. His former Ph.D. students hold tenure-track academic positions (U of South Florida, UB, IIT Kanpur in India, The Capital University of Medical Sciences in Beijing, China); post-doctoral positions at top Universities (Harvard, Stanford, Johns Hopkins, Univ. of Pennsylvania); or research and leadership positions in leading pharmaceutical/biotechnology companies (Shire Pharmaceuticals, Bristol-Myers Squibb, Merck, Biogen, Life Technologies, MedImmune and others).

Education

  • PhD, University of Michigan, Chemical Engineering, 1996
  • MA, Mathematics, University of Michigan, 1996
  • MS, University of Michigan, Chemical Engineering, 1992
  • B. Chem. Eng., Aristotle University, Greece, Chemical Engineering, 1991

Loading...

Loading...

Loading...

Loading...